Alle Storys
Folgen
Keine Story von Astellas European Foundation mehr verpassen.

Astellas European Foundation

Astellas European Foundation Announces Shortlist for Uro-Oncology Grant

England (ots/PRNewswire)

$150,000 Grant will be awarded on Saturday 27th September

The Astellas European Foundation has announced the shortlist for the 2014 Uro-Oncology Grant. The Grant programme supports basic medical and related scientific programmes which contribute to advancements in urological oncology. The five finalists include applications from The Netherlands, Portugal and Spain. The winner will be announced at an event in Madrid, Spain, on 27th September.

The Astellas European Foundation is a registered charity with the long-term goal of providing support for programmes and activities that advance our understanding of medicine and health. The winner of the Grant is selected by a Judging Faculty that includes independent European thought leaders.

The shortlist includes teams led by:
Professor Paula Videira, Nova University, Lisbon, Portugal
Dr. Wim Witjes, EAU Research Foundation, EAU Central Research Office, Arnhem, The
 Netherlands
Dr. Gabri van der Pluijm, Leiden University Medical Centre, The Netherlands
Professor António Araújo, Portuguese Institute of Oncology, Porto, Portugal
Dr Alvaro Aytes and Dr Josep Piulats, L'Hospitalet del Llobregat, Barcelona, Spain

Dr Ayad Abdulahad, Astellas European Foundation Trustee and Senior Vice President of Medical Affairs and Health Economics for Astellas Pharma EMEA, commented, "We have received enormous interest in the Grant, and this year alone we accepted 60 high-quality entries from research institutions and hospitals across Europe and also from South Africa. The Foundation looks forward to announcing the winner on Saturday, and is pleased to share the shortlist entrants who have succeeded in reaching the final stage."

The Foundation now offers annual Grants of $150,000 for Uro-Oncology, Functional Urology and Uro-Gynaecology, and Transplantation. For information regarding the Grant process please contact the Astellas European Foundation by email at aef@astellas.com or call +44(0)203-379-8039.

Notes to Editors

About The Astellas European Foundation

The Astellas European Foundation is a registered charity, formed in 2005, with the long-term goal of providing support for programmes and activities that contribute to the advancement of an increasingly healthy society. In line with this aim, the Foundation has made substantial donations to global charities. The Astellas European Foundation also supports Astellas employees in their private fundraising efforts for charitable causes. The Astellas European Foundation is registered with the Charity Commission for England and Wales, number 1036344.

The Astellas European Foundation was established by funding from Astellas Pharma Inc, but operates independently of it.

Contact:

For further information, please contact: Joe Barker, Astellas
European Foundation Manager, Tel: +44(0)203-379-8039, Email:
joe.barker@astellas.com

Weitere Storys: Astellas European Foundation
Weitere Storys: Astellas European Foundation
  • 24.03.2014 – 09:01

    New Hope for Organ Transplant Patients

    Chertsey, England (ots/PRNewswire) - A recent study supported by an Astellas European Foundation Grant has identified potential therapeutic targets for transplantation treatment research. The study, carried out by Dr Nuria Lloberas, examined whether changing specific proteins in the body leads to a reduction in the immuno-inflammatory response thus lowering the risk of organ rejection. Dr Lloberas, from Hospital ...

  • 19.08.2013 – 09:01

    Astellas European Foundation award winners identify key prostate cancer genes

    Chertsey, England (ots/PRNewswire) - Institut Bergonié researchers identify six genes with potential to play significant role in fight against high grade form of disease Just four years after receiving an Astellas European Foundation Urology Prize Fund Award, researchers at France's Institut Bergonié have achieved their goal of identifying new gene targets that could ...